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Proteasome inhibitor Bortezomib/Velcade has emerged as an effective anticancer therapy for the treatment of relapsed and/or
refractory multiple myeloma (MM), but prolonged treatment can be associated with toxicity and development of drug resistance. In
this review, we discuss the recent discovery of a novel proteasome inhibitor, NPI-0052, that is distinct from Bortezomib in its
chemical structure, mechanisms of action, and effects on proteasomal activities; most importantly, it overcomes resistance to
conventional and Bortezomib therapies. In vivo studies using human MM xenografts shows that NPI-0052 is well tolerated, prolongs
survival, and reduces tumour recurrence. These preclinical studies provided the basis for Phase-I clinical trial of NPI-0052 in relapsed/
refractory MM patients.
British Journal of Cancer (2006) 95, 961–965. doi:10.1038/sj.bjc.6603406 www.bjcancer.com
& 2006 Cancer Research UK
Keywords: protein degradation; proteasomes; multiple myeloma; novel therapy; apoptosis; drug resistance
                                  
The systemic regulation of protein synthesis and protein degrada-
tion is essential for normal cellular functioning. The ubiquitin–
proteasome pathway mediates intracellular protein degradation:
first, protein is marked with a chain of small polypeptides called
ubiquitin; E1 ubiquitin enzyme then activates ubiquitin and links
it to the ubiquitin-conjugating enzyme E2 in an ATP-dependent
manner; E3 ubiquitin ligase then links the ubiquitin molecule to
the protein; a long polypeptide chain of ubiquitin moieties is
formed; and finally, a multi-enzyme proteolytic complex 26S
proteasome degrades protein into small fragments in an ATP-
dependent manner. (Ciechanover and Schwartz, 1998; Goldberg
and Rock, 2002; Pickart, 2004). The 26S proteasome contains a
proteolytic core 20S and 19S regulatory subunits (Elliott and Ross,
2001; Goldberg and Rock, 2002; Ciechanover, 2003). The structure
of the 20S core consists of four stacked rings: two central beta rings
that are surrounded by two alpha rings, each consisting of seven
subunits (Figure 1). The 19S regulatory complex, consisting of a lid
and a base, binds to form the 20S proteasome holoenzyme. The lid
region of 19S recognises ubiquitinated proteins, whereas the base,
which caps the end of the 20S core contains six ATPase that
regulates unfolding of the protein substrates and directing them
into the catalytic chamber of the 20S core. The 20S proteasome
triggers the protein breakdown via its proteolytic activities.
Mutagenesis and structural studies show that beta-subunits of
the 20S proteasome have amino-terminal threonines that serve as
catalytic active sites (nucleophiles) (Figure 1). The three major
proteolytic activities are: b-5, chymotrypsin-like (CT-L) that
cleaves after hydrophobic residues; b-2, trypsin-like (T-L) that
cleaves after basic residues; and b-1, caspase-like (C-L), which
cleaves after acidic residues (Schechter and Berger, 1967; Cardozo,
1993; Lupas et al, 1993; Orlowski et al, 1993). In addition, these
three constitutive proteasome activities have corresponding
inducible immunoproteasomes b-5i, b-1i, b-2i with different
specificity (Uebel and Tampe, 1999; Kessler et al, 2001).
The substrates of the 26S proteasome include proteins mediating
various cellular functions such as transcription, stress response,
cell cycle regulation, oncogenesis, ribosome biogenesis, cellular
differentiation, and DNA repair (Ciechanover and Schwartz, 1998).
Defects in the complex biochemical machinery of UBP signalling
pathway are linked to the pathogenesis of many human diseases
(Myung et al, 2001). Targeting UBP signalling pathway has
therapeutic implication. For example, blockade of proteasome
activity results in stabilisation of inhibitory proteins, thereby
abrogating growth/survival and triggering apoptosis. Our pre-
clinical and clinical studies in multiple myeloma (MM) validated
20S as a therapeutic target and led to the FDA approval of the first
proteasome inhibitor Bortezomib (Velcade) for treatment of
relapsed/refractory MM (Hideshima and Anderson, 2002; Chauhan
et al, 2005b). Bortezomib therapy showed a remarkable overall
response rate (35%) in MM patients; however, it can be associated
with toxicity and development of drug resistance. Nonetheless, the
success of Bortezomib as an anticancer therapy renewed the
interest in discovery and development of other novel proteasome
inhibitors. Specifically, delineation of mechanisms mediating
interaction of proteasome inhibitors with 20S proteasome will
allow designing potent and therapeutically efficacious proteasome
inhibitors. In this context, our recent study characterised a novel
proteasome inhibitor NPI-0052, a small molecule derived from
fermentation of Salinospora, a new marine Gram-positive actino-
mycete (Feling et al, 2003; Macherla et al, 2005; Chauhan et al,
2005a). Importantly, NPI-0052 is distinct from Bortezomib, orally
bioactive, and an equipotent antitumour agent (Chauhan et al,
2005a).
CHEMICAL STRUCTURE AND PROTEASOME
ACTIVITY PROFILE OF NPI-0052 VIS-A `-VIS OTHER
PROTEASOME INHIBITORS
The proteasome inhibitors can be categorised into two groups:
natural products or synthetic analogues. The synthetic inhibitors
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been classified as peptide aldehydes, peptide boronates, peptide
benzamides, peptide vinyl sulphones, and peptide alpha-ketoalde-
hydes and peptide-alpha-ketoamides (Adams et al, 1999; Adams,
2004; Chauhan et al, 2005b). A well-characterised example of this
category of peptide-based proteasome inhibitor is Bortezomib, a
boronic acid dipeptide derivative which inhibits proteasome
function in a reversible manner via interaction of boronic acid at
the C-terminal of Bortezomib with an active threonine site in the
proteasome (Adams et al, 1999). On the other hand, the natural
product proteasome inhibitors exhibit scaffolds of core structures
and pharmacophores. Examples of this category include linear
peptide epoxyketones, peptide macrocycles, gamma-lactam thiol
ester, and fungal epipolythioldioxopiperazine toxin.
NPI-0052 is a nonpeptide proteasome inhibitor with structural
similarity to Omuralide (Corey and Li, 1999), a beta-lactone
derived from naturally occurring lactacystin. However, in contrast
to Omuralide, NPI-0052 has a uniquely methylated C3 ring
juncture, chlorinated alkyl group at C2, and cyclohexene ring at
C5 (Figure 1). Structure–activity relationship studies showed that
(1) replacement of chloroethyl group with unhalogenated sub-
stituents resulted in loss of potency in cell-based assays, and (2)
halogen exchange and cyclohexene ring epoxidation were well
tolerated, although some stereochemical modifications markedly
attenuated activity (Macherla et al, 2005). These data suggested
that whereas the beta-lactone is a key pharmachophre of both
Omuralide and NPI-0052, the enhanced potency of NPI-0052 is due
to the substituents in bicyclic ring system. A recent report
describing the crystal structure of NPI-0052 in complex with the
20S proteasome revealed an important consequence of beta-
lactone ring opening and a mechanism of irreversible binding vis-
a `-vis omuralide (Groll et al, 2006). Collectively, these structural
differences account for the enhanced in vitro and in vivo potency
of NPI-0052 compared to Omuralide (Feling et al, 2003; Macherla
et al, 2005; Groll et al, 2006).
NPI-0052 inhibits proteasome activity by covalently modifying
the active site threonine residues of the 20S proteasome (Corey and
Li, 1999). Comparative study of the effect of NPI-0052 and
Bortezomib on proteasomal activities using purified human
erythrocyte 20S proteasomes and flurogenic substrates shows that
(1) NPI-0052 inhibits CT-L and T-L activities at much lower
concentrations than Bortezomib, and (2) higher concentrations of
NPI-0052 than Bortezomib are required to inhibit C-L activity
(Chauhan et al, 2005a). Thus, Bortezomib and NPI-0052 differen-
tially affect all three proteasome activities: NPI-0052 at lower
concentrations targets CT-L and T-L, whereas Bortezomib
predominantly affects CT-L and C-L. In vivo animal studies using
whole-blood lysates showed that NPI-0052 completely blocked CT-
L activity, which was recoverable by day 7; whereas inhibition of
CT-L activity is restored at 24h after Bortezomib. A 50% inhibition
of T-L activity is noted upon NPI-0052 exposure, which is restored
by day 7; whereas Bortezomib increases T-L activity, which
remains elevated even at day 7. In the context of C-L activity, the
profiles of both NPI-0052 and Bortezomib showed similarity, that
is, marked inhibition upon initial exposure and recovery at day 7.
The likely reason for the late recovery of proteasome activity after
NPI-0052 may be owing to its binding characteristic to the 20S
proteasome. Nevertheless, the ability of NPI-0052 to trigger
sustained inhibition of CT-L, T-L and C-L (up to 7 days) has
clinical implications, that is, less frequent administration in
patients. Of note, Bortezomib is currently given twice weekly to
patients to achieve maximal CT-L inhibition (75–78%). The CT-L
activity inhibition in peripheral blood cells of patients is noted
within an hour of Bortezomib administration and recoverable
before the next dose (Adams, 2002; Hamilton et al, 2005).
As noted above, both NPI-0052 and Bortezomib differentially
inhibit proteasome activities. Whether inhibition of two or all
three proteolytic activities is therapeutically advantageous is now
being defined. A recent report examined the role of proteolytic
sites using site specific inhibitors on the degradation of several
model unfolded proteins (histones, casein, aged calmodulin, and
denatured ovalbumin) by purified mammalian 26S proteasome
(Kisselev et al, 2006). This study demonstrates that therapeutic
concentrations of Bortezomib which inhibit 75% of CT-L activity
only result in partial protein breakdown, that is 10–25%,
suggesting that protein breakdown machinery remains functional
despite Bortezomib exposure. Furthermore, a simultaneous
inhibition of multiple proteasome activities is a prerequisite for
a significant (i.e., 450%) proteolysis (Kisselev et al, 2006).
Another study showed that a 50% inhibition of cystic fibrosis
transmembrane conductance regulator degradation in reticulo-
cytes extracts required concurrent blockade of CT-L and C-L
proteasome activites (Oberdorf et al, 2001).
In vitro studies using purified 20S proteasomes showed that
NPI-0052 has lower EC50 for T-L than does Bortezomib. In vivo
animal model studies show marked inhibition of T-L activity in
response to NPI-0052, whereas Bortezomib enhances T-L protea-
some activity. A further confirmation of the ability of NPI-0052 to
block proteasomal activity was derived from experiments using a
novel methodology (instead of conventional use of flourogenic
substrate) to assess proteasome activity in MM cells. Specifically,

































Figure 1 Schematic representation of 26S proteasome composition: The three primary proteolytic activities (CT-L, T-L, and C-L) reside within the
b-subunits of 20S and interact with proteasome inhibitors. Bortezomib and NPI-0052 are structurally distinct with different active sites.
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all active proteasome subunits showed that NPI-0052 at the IC50
doses for MM cells reduced the dansylAhx3L3VS-labelling of the
b-5 (represents CT-L activity), b-1 (represents C-L activity), and
b-2 (represents T-L activity) subunits (Berkers et al, 2005).
Higher doses of Bortezomib are required to inhibit CT-L and
C-L activity, whereas little, if any, inhibition of T-L activity
was noted. Importantly, our study showed that MM cells exhibit
higher constitutive levels of T-L proteasome activity than either
CT-L or C-L activities (Crawford et al, 2006). These data, coupled
with the results that NPI-0052, but not Bortezomib, efficiently
inhibits CT-LþT-L activities (Chauhan et al, 2005a), suggest that
NPI-0052 may trigger more proteolysis than Bortezomib in MM
cells.
Besides the constitutive proteasome activities, NPI-0052 and
Bortezomib also affect the immunoproteasomes. Alterations in
immunoproteasome may have clinical implications by modulating
the immune response in MM patients. Our data suggest that both
NPI-0052 and Bortezomib differentially affect constitutive and
immunoproteasome in MM.1S MM cell line (Chauhan et al,
2005a). A novel methodology was applied to measure proteasome
activity by Western blot analysis using dansyl-Ahx3L3VS as a
probe (Berkers et al, 2005). NPI-0052 inhibits b-5i, b-2i, and b-1i
activities in MM cells. Slightly higher concentrations of Bortezo-
mib were required to achieve inhibition of b-5i, b-2i, and b-1i. A
recent study also showed that Bortezomib inhibits the immuno-
proteasome in MM cells (Altun et al, 2005). It is likely that
blockade of one or more of these proteasomal activities along with
the kinetics of inhibition confer therapeutic advantage. Moreover,
previous reports showed that different organs/cell types express
different ratios of constitutive-, immuno-, and hybrid-proteasomes
(Stohwasser et al, 1997; Dahlmann et al, 2000; Crawford et al,
2006). Our ongoing studies using MM patient cells and a panel of
MM cell lines are addressing these questions by designing more
sensitive and specific proteasome probes against each proteasome
subunits. These studies will further delineate the differential
impact of NPI-0052 and Bortezomib on both constitutive
proteasome activities and immunoproteasomes.
IN VITRO AND IN VIVO ANTITUMOUR ACTIVITY
OF NPI-0052
Initial screening of NPI-0052 against the NCI panel of 60 tumour
cell lines showed GI50 of o10nM in all cases (Feling et al, 2003). In
concert with these observations, our data showed that (1) NPI-
0052 induces apoptosis in MM cells sensitive and resistant to
conventional and Bortezomib therapies; and (2) IC50 of NPI-0052
for MM cells is within the low nanomolar concentration (Chauhan
et al, 2005a). Importantly, NPI-0052 similarly triggered apoptosis
in purified tumour cells from several MM patients relapsing after
various prior therapies including Bortezomib and thalidomide.
Although the cells from Bortezomib-refractory patients remain
sensitive (15–50%) to the treatment with Bortezomib in vitro, our
data suggest that NPI-0052 is a more potent inducer of these cells.
The variable in vitro cytotoxicity of NPI-0052 and Bortezomib may
be owing to their distinct mode of action in MM cells including
differential effects on proteasome activities. Given that therapeutic
concentrations of Bortezomib primarily target CT-L activity, the
other two proteolytic activities may compensate, thereby main-
taining the functionality of proteasome. On the other hand, NPI-
0052 inhibits all three proteolytic activities, thereby achieving
maximal proteolysis. Moreover, mechanisms conferring Bortezo-
mib resistance may not be effective against NPI-0052. Nonetheless,
our study suggests that NPI-0052 is a potent inducer of MM cells
apoptosis in tumour cells obtained from Bortezomib-refractory
MM patients. Development of Bortezomib-resistant MM cell lines
will further elucidate this issue.
Drug resistance in MM cells is conferred, in part, by the bone
marrow (BM) microenvironment. Adhesion of MM cells with BM
stromal cells (BMSCs) induces cytokine secretion, which induce
paracrine growth of MM cells and protect against drug-induced
apoptosis (Hideshima and Anderson, 2002). Our findings show
that NPI-0052, like Bortezomib, inhibits the secretion of BMSCs-
derived MM cell growth factor IL-6 within the BM milieu, without
affecting the viability of MM BMSCs. Furthermore, NPI-0052
triggers MM cell apoptosis even in the presence of IL-6 or IGF-I.
Similarly, NPI-0052 abrogates VEGF-triggered migration (Podar
et al, 2002) of MM cells, suggesting NPI-0052 as an antimigratory
agent. Whether MM cell interaction with BM components affects
the proteasome activity profiles of either MM cells or BMSCs is
unclear. Of note, we have shown that MM-BMSC binding
upregulate transcript levels of 26S proteasome subunits, which
may serve to meet the increased demand for protein synthesis and
protein degradation in MM cells. This may also explain higher
sensitivity of MM cells to proteasome inhibitor exposure in the BM
microenvironment.
Given that protein degradation is required for normal cellular
progression, it is imperative to examine the effect of proteasome
inhibitors on normal cell viability and proteasome activity.
Comparative examination of the effects of NPI-0052 and Bortezo-
mib on normal lymphocytes showed that NPI-0052 does not
significantly decrease normal lymphocyte viability at the IC50
doses for MM cells, with modest effects only at higher concentra-
tions of NPI-0052. By contrast, Bortezomib decreased the survival
of lymphocytes at the concentrations close to the IC50 doses for
MM cells. The impact of NPI-0052 on proteasome activity showed
that NPI-0052 inhibits CT-L activity, even at the doses that does
not trigger apoptosis in MM cells. Earlier observations that
Bortezomib inhibits 20S proteasome activity in murine WBCs at
1h post injections, and that a similar degree of proteasome
inhibition was noted in blood from responders vs non-responders
to Bortezomib therapy (Adams, 2002; Richardson, 2004), suggest
that inhibition of proteasome activity in blood may not correlate to
cytotoxicity. The mechanism whereby proteasome inhibitors block
proteasome activity without triggering apoptosis is unclear. One
possibility is that proteasome inhibition in normal cells is
compensated by alternative intact protein breakdown mechanisms
such as lysosomal pathways, which will allow for uninterrupted
protein degradation. In addition, cancer cells, in contrast to
normal cells, have abnormal protein synthesis (e.g., high immuno-
globulins secretion in MM), resulting in increased dependence on
proteasomes to degrade misfolded proteins (which also explains
the increased sensitivity of MM cells to proteasome inhibition).
Nonetheless, the above data suggest that NPI-0052, in contrast to
Bortezomib, is likely to have less toxic effects than Bortezomib
on normal lymphocytes cells.
Examination of the in vivo efficacy of NPI-0052 using a human
plasmacytoma xenograft mouse model showed potent antitumour
activity of NPI-0052 given orally (LeBlanc et al, 2002; Chauhan
et al, 2005a). Treatment of tumour bearing mice with NPI-0052,
but not vehicle alone, inhibited MM tumour growth and prolongs
survival of these mice. NPI-0052 doses were well tolerated by mice,
without significant weight loss or any neurological behavioural
changes. Importantly, analysis at day 300 showed no recurrence of
tumour in 57% of the NPI-0052-treated mice. A head-to-head
examination of NPI-0052 and Bortezomib showed that both agents
reduced tumour progression and prolonged survival.
MECHANISTIC INSIGHTS INTO NPI-0052 TRIGGERED
CELL DEATH
Nuclear factor-kappa B (NF-kB) is a major growth and survival
signalling pathway in MM; indeed, the initial rationale for
therapeutic use of Bortezomib was, in part, based on its ability
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Hideshima et al, 2002). Comparative analysis of the effect of NPI-
0052 and Bortezomib on NF-kB showed that NPI-0052 is a more
potent inhibitor of NF-kB and related cytokine transcription and
secretion than Bortezomib. These findings show that NPI-0052,
like Bortezomib, targets NF-kB. Importantly, blockade of NF-kB
also have implication in modulating immune responses, as NF-kB
play a role during T-cell activation and function. A recent study
showed that blockade of NF-kB using Bortezomib triggered cell
death in activated T cells along with decreased production of Th1
cytokines (INF-g and IL-2) (Blanco et al, 2006). Because NPI-0052
is an irreversible inhibitor, it may similarly inhibit T-cell function
via NF-kB modulation; and, our current studies are examining this
question using MM patient-derived T-cells and normal resting or
activated T cells.
Our studies in MM cells showed that NPI-0052-, like Bortezo-
mib, -induced apoptosis, is associated with activation of both
extrinsic (caspase-8-mediated) and intrinsic (caspase-9-mediated)
cell-death signalling pathways (Chauhan et al, 2005a). Specifically,
NPI-0052-induced MM cell death correlates with (1) decrease in
DCm; (2) increase in O2  production; (3) the release of
cytochrome c and smac from mitochondria to cytosol; and (4)
activation of caspase-9, caspase-8, and caspase-3, followed by
PARP cleavage. The requirement for caspase-8 vs caspase-9 during
NPI-0052- and Bortezomib-induced apoptosis was further defined
using both biochemical inhibitors and dominant-negative strate-
gies. Our data demonstrated that (1) NPI-0052-induced MM cell
apoptosis is predominantly mediated by caspase-8; and (2)
Bortezomib-induced apoptosis requires both caspase-8 and
caspase-9 activation (Figure 2). These findings suggest that NPI-
0052 relies more on FADD–caspase-8 signalling axis than does
Bortezomib, further confirming differential action of NPI-0052 vs
Bortezomib in MM cells. Studies using Bax/Bak DKO further
showed that, in contrast to NPI-0052-, Bortezomib-mediated cell
death requires mitochondrial apoptotic signalling via Bax and Bak.
Moreover, ectopic expression of antiapoptotic protein Bcl-2
provided more protection against Bortezomib than NPI-0052 in
MM cells.
The mechanistic differences between NPI-0052 and Bortezomib,
that is, their effect on proteasome activities and their dependence
on specific apoptotic signal transduction pathways, provides the
basis for combination regimens for the treatment of MM. As
observed in our study (Chauhan et al, 2005a), the combination of
NPI-0052 with Bortezomib induced synergistic anti-MM activity,
without significantly affecting the viability of normal lymphocytes.
The mechanisms mediating enhanced cytotoxicity of the combina-
tion regimen may simply reflect higher levels of proteasome
inhibition with the two-drug regimen and/or differential apoptotic
signalling pathways. Nonetheless, the benefit of combined regimen
can only be established after a future clinical trial.
CONCLUDING REMARKS
As the ubiquitin–proteasome pathway regulates many essential
cellular processes, proteasome inhibitors offer a great promise as
therapeutic agents. Our study has evaluated the potential of a novel
proteasome inhibitor NPI-0052 as an anticancer agent. NPI-0052
inhibits proteasome activity both in vitro and in vivo at clinically
achievable doses, and induces a different proteasome inhibition
profile than Bortezomib. NPI-0052 is a more potent inhibitor of
NF-kB and related cytokine secretion than Bortezomib. NPI-0052
induces apoptosis in MM cells resistant to conventional and
Bortezomib therapies, without significantly affecting normal
lymphocyte viability. Importantly, NPI-0052, like Bortezomib, kills
MM cells even in the presence of protective BM microenvironment
without affecting the viability of BM cells. Moreover, NPI-0052
overcomes drug resistance conferred by the antiapoptotic protein
Bcl-2. NPI-0052 given orally inhibits MM tumour growth in vivo as
well as prolongs survival, without recurrence of tumour in 57%
mice. Biochemical and genetic evidence indicates that NPI-0052, in
contrast to Bortezomib, relies more on FADD-caspase-8-mediated
cell death signalling. Finally, combinations of low doses of NPI-
0052 and Bortezomib trigger synergistic anti-MM activity. Overall,
our study provides the rationale for clinical protocols evaluating
NPI-0052 to inhibit tumour cell growth, overcome conventional
chemotherapy and Bortezomib resistance, limit toxicity profiles,
and improve patient outcome in MM.
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